Magnesium Lithospermate B

Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroinflammation and attenuates neurodegeneration .

In Vitro

Magnesium Lithospermate B (20-60 μg/ml; 24 h) decreases LDH activity in the cultured supernatant, increases SOD activity in cardiomyocytes, reduces intracellular ROS and MDA levels, and significantly suppresses cardiomyocytes apoptosis. Magnesium Lithospermate B (1-100 μg/ml) enhances proliferation of neural stem cells (NSCs) in a dose-dependent manner. Magnesium Lithospermate B (10 μg/ml) promotes the differentiation in vitro of NSCs towards neurons. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Magnesium Lithospermate B (2-8 mg/kg; p.o. once daily for 16 d) reduces the renal damage of oxidative stress through reduction of reactive oxygen species in old rats . Magnesium Lithospermate B (0.5 μg/g; s.c. for 6 weeks) promotes the neurogenesis and improves the memory in PD models. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Young (5-month-old) and old (20-month-old) specific-pathogen-free male Sprague-Dawley rats Dosage: 2, 8 mg/kg Administration: P.o. once daily for 16 days Result: Reduced the protein expression of major subunits of nicotinamide adenine dinucleotide phosphate oxidase (Nox4 and p22phox), phospho-p38, nuclear factor-kappa B p65, cyclooxygenase-2, and inducible nitric oxide synthase. Showed lower levels of senescence-related proteins such as p16, ADP-ribosylation factor 6, p53, and p21.